Physician profile
Kyle R Thomas
NPI 1659064350
$1,018.20
in general payments reported to CMS, 2019-2025
14 companies · $276 in 2025
The $276 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $124 · 2024: $618 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $973 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.20 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $299.88 | 2023-2025 | Mounjaro, Jardiance |
| Abbvie INC. | $192.29 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $76.46 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $72.26 | 2024-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $69.14 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $63.48 | 2024-2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $54.98 | 2024-2025 | Austedo Xr, Austedo Xr |
| Pfizer INC. | $37.41 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $35.81 | 2024-2025 | Gvoke Hypopen |
| Insulet Corporation | $33.21 | 2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.65 | 2023-2024 | Tradjenta, Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.87 | 2023 | Xifaxan |
| Cequr Corporation | $17.75 | 2024 | Cequr Simplicity |
| Glaxosmithkline, LLC. | $14.01 | 2024 | Shingrix, Bexsero, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.